Investigating the JAK/STAT Pathway in Sarcoidosis Granuloma Cells
Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells
Assistance Publique - Hôpitaux de Paris · NCT04751279
This study is trying to see if a specific pathway in the body is linked to severe sarcoidosis in patients who don't respond to regular treatments, to find out who might benefit from new targeted therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris (other) |
| Locations | 1 site (Bobigny) |
| Trial ID | NCT04751279 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of the JAK/STAT signaling pathway in patients with sarcoidosis, particularly those with severe forms of the disease that do not respond to standard treatments. Researchers will evaluate blood samples from patients diagnosed with mediastinopulmonary sarcoidosis to assess the activation of the JAK/STAT pathway and its relationship with granuloma formation and disease severity. The study seeks to identify which patients may benefit from targeted therapies aimed at this pathway.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with mediastinopulmonary sarcoidosis at various stages of pulmonary involvement.
Not a fit: Patients who are pregnant or those who oppose participation in the study will not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment options for patients with severe sarcoidosis.
How similar studies have performed: Other studies have suggested the potential of targeting the JAK/STAT pathway in sarcoidosis, but this specific approach is still under investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a diagnosis of mediastinopulmonary sarcoidosis made according to ATS / ERS / WASOG criteria * Or patient suspected of having mediastino-pulmonary sarcoidosis, without any other probable causal factor identified on the usual standard examination at the time of the sample with the need for diagnostic confirmation at the end of the study according to the criteria of the ATS / ERS / WASOG * Sarcoidosis with stage 1 to 4 pulmonary involvement * Patients who had a chest CT scan in the 6 months preceding the sample. Examination carried out as part of routine care Exclusion Criteria: * Pregnancy. * Opposition expressed to participation in the study. * Patients on State Medical Aid.
Where this trial is running
Bobigny
- Service de pneumologie Hôpital Avicenne — Bobigny, France (RECRUITING)
Study contacts
- Principal investigator: Florence JENY, MD — Assistance Publique - Hôpitaux Paris
- Study coordinator: Florence JENY, MD
- Email: florence.jeny@aphp.fr
- Phone: 0148955129
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sarcoidosis, JAK-STAT Pathway Deregulation, JAK/STAT